Lenvatinib和Pembrolizumab在大多数非透明细胞肾细胞癌的治疗中发挥了作用，但罕见的组织学仍然落后

IF 25.2 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-09-15 DOI:10.1016/j.eururo.2025.08.009

Nazli Dizman, Hedyeh Ebrahimi, Alexander Chehrazi-Raffle

引用次数: 0

摘要

没有抽象的

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lenvatinib and Pembrolizumab Move the Needle for Most Non–clear-cell Renal Cell Carcinomas, Yet Rare Histologies Still Lag Behind

No Abstract

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.